The Cure IBM Blog
Arimoclomol for Inclusion Body Myositis – Clinical Trial Results
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success....
$68,245 Grant Available for Study of Inclusion Body Myositis
The Orphan Disease Center 2020 Million Dollar Bike Ride Grant Program is offering a $68,245 grant for the study of inclusion body myositis (IBM). Researchers from around the world are eligible to apply. Letters of Interest are due Friday, September 18. The grant is...
You can Bike, Walk, Run, or Ride for IBM on Saturday, June 13!
JOIN US! On June 13, you can support the cause of inclusion body myositis by biking, walking, running, swimming, or riding in your own town or city. The Million Dollar Bike Ride has become a virtual event this year. Although it is unfortunate that Team Cure IBM cannot...
The Million Dollar Bike Ride Needs YOUR Help!
Due to the coronavirus pandemic, Team Cure IBM will not be able to ride our bikes in Philadelphia this summer. However, although the University of Pennsylvania, the sponsor of the Million Dollar Bike Ride (MDBR), has cancelled the ride, the MDBR will still continue as...
Orphazyme Update Regarding Arimoclomol Clinical Trial During Coronavirus Pandemic
Thomas Blaettler, MD, the Chief Medical Office of Orphazyme, has released a statement to the global community regarding the status of the ongoing arimoclomol clinical trials during the coronavirus (COVID-19) pandemic. Arimoclomol is currently being studied for...
Caution Regarding the Use of Chloroquine to Treat Coronavirus in Myositis Patients
The following is a message written by Tom Lloyd, MD, a myositis specialist at the Johns Hopkins Medical Center. Can Chloroquine Cure Coronavirus? Not so fast… In a press conference today, President Trump discussed what the FDA was doing to accelerate approval of...
AAVogen Seeks Investment Funding for Development of New Therapy to Treat Inclusion Body Myositis
AAVogen, an early-stage biotech company, is developing a new treatment for inclusion body myositis (IBM). AVGN7 is a novel gene therapy treatment that is designed to treat IBM and other muscle wasting conditions. AAVogen has raised $2.3 million to date, mostly from...
$102,340 Grant Awarded for Inclusion Body Myositis Research
The 2019 Million Dollar Bike Ride grant of $102,340 for inclusion body myositis (IBM) research has been awarded to Dr. Steven A. Greenberg of Brigham and Women’s Hospital and Harvard Medical School. Dr. Greenberg will study, “Development of a Chemokine Targeted...
New Research Regarding Hand Function in Inclusion Body Myositis
A recently published study finds that the Inclusion Body Myositis Functional Rating Scale (IBMFRS) does not correlate as well as expected with measures of grip strength and finger flexor strength. This suggests that the IBMFRS could be improved to more accurately...
Arimoclomol Receives FDA Fast Track Designation for Inclusion Body Myositis
Arimoclomol, an investigational drug currently in a Phase 2/3 trial for inclusion body myositis (IBM), has received Fast Track designation from the FDA for treatment of this disabling muscle disease. This designation is designed to shorten the time needed for the FDA...
Support IBM Research
Join Cure IBM in the fight against Inclusion Body Myositis. Your support will help fund research and the development of treatment options for this debilitating disease.